Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients.
Domenico GalatiSerena ZanottaMariaelena CaponeGabriele MadonnaDomenico MallardoMarilena RomanelliEster SimeoneLucia FestinoFrancesca SparanoRosa AzzaroRosaria De FilippiAntonello PintoChrystal M PaulosPaolo Antonio AsciertoPublished in: Journal of translational medicine (2023)
T lymphocytes represent potential biomarkers whose perturbations are associated with reduced survival and worse clinical outcomes in melanoma patients.